AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 24145706 — intervention group
Group type: COMPARATOR
Intervention: Sevoflurane and air
Number of subjects: 52
Study 24145706 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol and nitrous oxide
Number of subjects: 52
Study 24145706 — intervention group
Group type: COMPARATOR
Intervention: Propofol and air
Number of subjects: 52
Study 21038106 — intervention group
Group type: EXPERIMENTAL
Intervention: Target biopsy
Number of subjects: 0
Study 21038106 — intervention group
Group type: COMPARATOR
Intervention: Step biopsy
Number of subjects: 0
Study 18703549 — intervention group
Group type: EXPERIMENTAL
Intervention: Dorzolamide/timolol fixed combination (DTFC)
Number of subjects: 31
Study 18703549 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost/timolol fixed combination (LTFC)
Number of subjects: 31
Study 18703549 — intervention group
Group type: EXPERIMENTAL
Intervention: Addition of dorzolamide/timolol fixed combination (DTFC) to latanoprost monotherapy
Number of subjects: 31
Study 18703549 — intervention group
Group type: COMPARATOR
Intervention: Latanoprost monotherapy
Number of subjects: 31
Study 16939542 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20-80 mg/day
Number of subjects: 6801
Study 16939542 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6801
Study 16939542 — intervention group
Group type: COMPARATOR
Intervention: Fluvastatin vs Placebo
Number of subjects: 6801
Study 14648726 — intervention group
Group type: EXPERIMENTAL
Intervention: Ligasure Vessel Sealing System
Number of subjects: 80
Study 14648726 — intervention group
Group type: COMPARATOR
Intervention: Conventional haemostatic methods
Number of subjects: 80
Study 11095257 — intervention group
Group type: EXPERIMENTAL
Intervention: PTMR with a holmium:YAG laser plus continued medical treatment
Number of subjects: 221
Study 11095257 — intervention group
Group type: COMPARATOR
Intervention: Continued medical treatment only
Number of subjects: 221
Study 11095257 — intervention group
Group type: EXPERIMENTAL
Intervention: PTMR
Number of subjects: 221
Study 11095257 — intervention group
Group type: COMPARATOR
Intervention: Medical treatment
Number of subjects: 221
Study 8628460 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 micrograms/kg rHCNTF
Number of subjects: 730
Study 8628460 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 micrograms/kg rHCNTF
Number of subjects: 730
Study 8628460 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 730
Study 8233620 — intervention group
Group type: EXPERIMENTAL
Intervention: Lambda-cyhalothrin impregnated bed nets
Number of subjects: 1500
Study 8233620 — intervention group
Group type: COMPARATOR
Intervention: Maloprim
Number of subjects: 1500
Study 8233620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1500
Study 2440626 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatinum alone or in combination with bleomycin, methotrexate or 5-fluorouracil
Number of subjects: 129
Study 2440626 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatinum treatment
Number of subjects: 129
Study 2440626 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatinum treatment in advanced previously untreated disease
Number of subjects: 129
Study 29908670 — intervention group
Group type: EXPERIMENTAL
Intervention: upadacitinib 15 mg
Number of subjects: 499
Study 29908670 — intervention group
Group type: EXPERIMENTAL
Intervention: upadacitinib 30 mg
Number of subjects: 499
Study 29908670 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 499
Study 25495390 — intervention group
Group type: EXPERIMENTAL
Intervention: Treated low thyroid hormone group
Number of subjects: 480
Study 25495390 — intervention group
Group type: COMPARATOR
Intervention: Untreated low thyroid hormone group
Number of subjects: 480
Study 25495390 — intervention group
Group type: COMPARATOR
Intervention: Normal thyroid functioning group
Number of subjects: 480
Study 22272730 — intervention group
Group type: EXPERIMENTAL
Intervention: mild procedure
Number of subjects: 38
Study 22272730 — intervention group
Group type: COMPARATOR
Intervention: Epidural steroid injection (ESI)
Number of subjects: 38
Study 20194711 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 infusion
Number of subjects: 23
Study 20194711 — intervention group
Group type: EXPERIMENTAL
Intervention: Amylin infusion
Number of subjects: 23
Study 20194711 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 and amylin infusions
Number of subjects: 23
Study 19148430 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg
Number of subjects: 100
Study 19148430 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 15839293 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidisciplinary case management model
Number of subjects: 0
Study 15839293 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient education materials and modified clinical policy
Number of subjects: 0
Study 12220763 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin
Number of subjects: 211
Study 12220763 — intervention group
Group type: COMPARATOR
Intervention: External pneumatic compression
Number of subjects: 211
Study 10486678 — intervention group
Group type: EXPERIMENTAL
Intervention: 110 dB noise
Number of subjects: 12
Study 10486678 — intervention group
Group type: EXPERIMENTAL
Intervention: 95 dB noise
Number of subjects: 12
Study 10486678 — intervention group
Group type: EXPERIMENTAL
Intervention: 120 dB noise
Number of subjects: 12
Study 10486678 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation (0 dB)
Number of subjects: 12
Study 7762497 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-acting diltiazem 300 mg/day and aspirin 160 mg/day
Number of subjects: 920
Study 7762497 — intervention group
Group type: COMPARATOR
Intervention: Aspirin 160 mg/day alone
Number of subjects: 920
Study 2086672 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta ser (IFN-beta ser) 4.5 x 10(6) units
Number of subjects: 64
Study 2086672 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta ser (IFN-beta ser) 90 x 10(6) units
Number of subjects: 64
Study 2086672 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-beta ser (IFN-beta ser)
Number of subjects: 64
Study 492836 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin (15 mg/kg)
Number of subjects: 24
Study 492836 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (25 mg/kg)
Number of subjects: 24
Study 492836 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 24
Study 30982177 — intervention group
Group type: EXPERIMENTAL
Intervention: Fractional 1550-nm erbium-glass laser combined with 5% minoxidil
Number of subjects: 30
Study 30982177 — intervention group
Group type: COMPARATOR
Intervention: 5% minoxidil alone
Number of subjects: 30
Study 27774838 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 4631
Study 27774838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4631
Study 25398434 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (OXT)
Number of subjects: 70
Study 23844756 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral combination of diosmin (300 mg/day), C. asiatica (15 mg/day) and Melilotus (160 mg/day)
Number of subjects: 70
Study 23844756 — intervention group
Group type: COMPARATOR
Intervention: Control group (untreated)
Number of subjects: 70
Study 23844756 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 70
Study 22013932 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin
Number of subjects: 76
Study 22013932 — intervention group
Group type: COMPARATOR
Intervention: Enoxaparin
Number of subjects: 76
Study 22013932 — intervention group
Group type: EXPERIMENTAL
Intervention: Nadroparin (excessive dosage)
Number of subjects: 76
Study 22013932 — intervention group
Group type: COMPARATOR
Intervention: Nadroparin (reduced dosage)
Number of subjects: 76
Study 19211706 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (TU) 160 mg/day
Number of subjects: 322
Study 19211706 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 322
Study 19211706 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (TU) 80 mg/day
Number of subjects: 322
Study 19211706 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (TU) 240 mg/day
Number of subjects: 322
Study 16430930 — intervention group
Group type: EXPERIMENTAL
Intervention: Human contact session (45 min of interaction including playing, grooming, petting, and reviewing basic obedience commands)
Number of subjects: 0
Study 16430930 — intervention group
Group type: COMPARATOR
Intervention: No human contact session
Number of subjects: 0
Study 15561256 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus (TAC)
Number of subjects: 21
Study 15561256 — intervention group
Group type: COMPARATOR
Intervention: Cyclosporine (CsA)
Number of subjects: 21
Study 11379836 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 1637
Study 11379836 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 1637
Study 11379836 — intervention group
Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 1637
Study 9642379 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose magnesium gluconate (3 g/day)
Number of subjects: 102
Study 9642379 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 3556202 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose budesonide (1600 micrograms/day)
Number of subjects: 24
Study 3556202 — intervention group
Group type: COMPARATOR
Intervention: Low-dose budesonide (400 micrograms/day)
Number of subjects: 24
Study 30368346 — intervention group
Group type: EXPERIMENTAL
Intervention: Pilates Reformer intervention
Number of subjects: 55
Study 30368346 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 55
Study 27400657 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory intervention providing all general practitioners with a starting package of 10 iFOBTs, clinical instruction on iFOBT use, and online information material; optional continuous medical education on colorectal cancer diagnostics and use of iFOBT.
Number of subjects: 836
Study 26578370 — intervention group
Group type: EXPERIMENTAL
Intervention: OsteoACTIVE (exercise programme and patient education)
Number of subjects: 80
Study 26578370 — intervention group
Group type: COMPARATOR
Intervention: Patient education only (control group)
Number of subjects: 80
Study 23896630 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensity Modulated Radiotherapy (IMRT)
Number of subjects: 57
Study 23896630 — intervention group
Group type: COMPARATOR
Intervention: 3D Conformal Radiotherapy (3D-RT)
Number of subjects: 57
Study 20034362 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin 20 mg
Number of subjects: 49
Study 20034362 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 49
Study 18840378 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fresh gas flow balanced anesthesia (LFGF SS) with inhalational sevoflurane and IV sufentanil in a target controlled infusion
Number of subjects: 60
Study 18840378 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fresh gas flow balanced anesthesia (LFGF SS)
Number of subjects: 60
Study 18840378 — intervention group
Group type: COMPARATOR
Intervention: IV anesthesia (TCI)
Number of subjects: 60
Study 16373160 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation and plication
Number of subjects: 700
Study 16373160 — intervention group
Group type: COMPARATOR
Intervention: Milligan‐Morgan hemorrhoidectomy
Number of subjects: 700
Study 12798559 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial prevention and antitachycardia pacing (ATP) ON
Number of subjects: 368
Study 12798559 — intervention group
Group type: COMPARATOR
Intervention: DDDR pacing at a lower programmed rate of 60 ppm (OFF group)
Number of subjects: 368
Study 11119738 — intervention group
Group type: EXPERIMENTAL
Intervention: IVF
Number of subjects: 71
Study 11119738 — intervention group
Group type: COMPARATOR
Intervention: Control (normal menstrual cycle)
Number of subjects: 71
Study 8841162 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical nutrition therapy from a registered dietitian (one or three visits) in addition to physician or nurse counseling and Grocery Shopping Guide.
Number of subjects: 104
Study 8841162 — intervention group
Group type: COMPARATOR
Intervention: Counseling by a physician or nurse (control group).
Number of subjects: 104
Study 1634641 — intervention group
Group type: EXPERIMENTAL
Intervention: Lovastatin
Number of subjects: 35
Study 6662159 — intervention group
Group type: COMPARATOR
Intervention: Clonidine (0.3 mg p.o.)
Number of subjects: 8
Study 6662159 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.3 mg p.o.) plus maprotiline (100 mg in 4 divided doses over 22 h)
Number of subjects: 8
Study 6662159 — intervention group
Group type: EXPERIMENTAL
Intervention: Maprotiline (100 mg in 4 divided doses over 22 h)
Number of subjects: 8
Study 6662159 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 30845034 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacroiliac joint arthrodesis with triangular titanium implants
Number of subjects: 103
Study 30845034 — intervention group
Group type: COMPARATOR
Intervention: Conservative management
Number of subjects: 103
Study 28391703 — intervention group
Group type: EXPERIMENTAL
Intervention: MyFamilyPlan online preconception health education module
Number of subjects: 292
Study 28391703 — intervention group
Group type: COMPARATOR
Intervention: Standard online preconception health education materials (Control)
Number of subjects: 292
Study 26318445 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger (2 g/day of ginger powder for 12 weeks)
Number of subjects: 80
Study 26318445 — intervention group
Group type: COMPARATOR
Intervention: Placebo (corn starch as two 1 g tablets for 12 weeks)
Number of subjects: 80
Study 26318445 — intervention group
Group type: EXPERIMENTAL
Intervention: Ginger
Number of subjects: 80
Study 25257359 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose 300,000-IU intramuscular injection of vitamin D3
Number of subjects: 380
Study 25257359 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 380
Study 22643160 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (minimum of 20 minutes, three times per week, at 55% of maximal aerobic capacity)
Number of subjects: 60
Study 22643160 — intervention group
Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 60
Study 20705215 — intervention group
Group type: EXPERIMENTAL
Intervention: Tricyclic antidepressants
Number of subjects: 174
Study 20705215 — intervention group
Group type: EXPERIMENTAL
Intervention: Serotonin noradrenaline reuptake inhibitors
Number of subjects: 174
Study 20705215 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin
Number of subjects: 174
Study 20705215 — intervention group
Group type: EXPERIMENTAL
Intervention: Pregabalin
Number of subjects: 174
Study 20705215 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioids
Number of subjects: 174
Study 20705215 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 174
Study 17186393 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin at target INR range of 2.1-3.0
Number of subjects: 114
Study 17186393 — intervention group
Group type: COMPARATOR
Intervention: Warfarin at target INR range of 3.1-4.0
Number of subjects: 114
Study 15110397 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants (AO: 1000 mg vitamin C and 300 mg RRR‐alpha‐tocopheryl acetate)
Number of subjects: 22
Study 15110397 — intervention group
Group type: COMPARATOR
Intervention: Placebos (PL)
Number of subjects: 22
Study 15110397 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants (AO)
Number of subjects: 22
Study 12235304 — intervention group
Group type: EXPERIMENTAL
Intervention: Learning test (memory)
Number of subjects: 5804
Study 12235304 — intervention group
Group type: EXPERIMENTAL
Intervention: Coding test (general speed)
Number of subjects: 5804
Study 12235304 — intervention group
Group type: EXPERIMENTAL
Intervention: Short version of the Stroop test (attention)
Number of subjects: 5804
Study 12235304 — intervention group
Group type: EXPERIMENTAL
Intervention: All tests
Number of subjects: 5804
Study 9680495 — intervention group
Group type: EXPERIMENTAL
Intervention: Albuterol (200 micrograms administered via a Volumatic spacer)
Number of subjects: 46
Study 9680495 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbachol responsiveness
Number of subjects: 46
Study 9680495 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic anti-inflammatory treatment
Number of subjects: 46
Study 8205569 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemopump cardiac assist system
Number of subjects: 0
Study 8205569 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemopump for circulatory support during aorto-coronary artery surgery
Number of subjects: 0
Study 8205569 — intervention group
Group type: EXPERIMENTAL
Intervention: Hemopump for high-risk angioplasty
Number of subjects: 0
Study 2643863 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 0
Study 2643863 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril
Number of subjects: 0
Study 2643863 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (in combination)
Number of subjects: 0
Study 31790853 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural case management (CBCM)
Number of subjects: 304
Study 29930261 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) injections
Number of subjects: 24
Study 29930261 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal (IN) injections
Number of subjects: 24
Study 29930261 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous (SC) injections
Number of subjects: 24
Study 29930261 — intervention group
Group type: COMPARATOR
Intervention: Null control
Number of subjects: 24
Study 29203734 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (15 mg once daily for 6 months)
Number of subjects: 43
Study 25600818 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 0
Study 25600818 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS
Number of subjects: 0
Study 25600818 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal and anodal stimulation
Number of subjects: 0
Study 25600818 — intervention group
Group type: COMPARATOR
Intervention: tDCS (both anodal and cathodal)
Number of subjects: 0
Study 24016492 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus early rhythm control therapy (antiarrhythmic drugs, catheter ablation, and patient-operated ECG device)
Number of subjects: 3000
Study 24016492 — intervention group
Group type: COMPARATOR
Intervention: Usual care (anticoagulation, therapy of underlying heart disease, and rate control)
Number of subjects: 3000
Study 24016492 — intervention group
Group type: EXPERIMENTAL
Intervention: Usual care plus early rhythm control therapy
Number of subjects: 3000
Study 21085884 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention (telephone interviews and workshops)
Number of subjects: 1467
Study 21085884 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1467
Study 18031595 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide (60 or 120 mcg with major meals)
Number of subjects: 211
Study 18031595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 18031595 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramlintide
Number of subjects: 211
Study 16749292 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational interventions targeting cardiologists
Number of subjects: 0
Study 16749292 — intervention group
Group type: COMPARATOR
Intervention: Guideline recommendations for acute coronary syndromes
Number of subjects: 0
Study 14579210 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 295
Study 14579210 — intervention group
Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 295
Study 10762522 — intervention group
Group type: COMPARATOR
Intervention: CSF ferritin levels
Number of subjects: 16
Study 10762522 — intervention group
Group type: COMPARATOR
Intervention: CSF transferrin levels
Number of subjects: 16
Study 8653096 — intervention group
Group type: EXPERIMENTAL
Intervention: Imagery study task during initial study period
Number of subjects: 0
Study 1450143 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrievette
Number of subjects: 217
Study 1450143 — intervention group
Group type: EXPERIMENTAL
Intervention: Emmett
Number of subjects: 217
Study 1450143 — intervention group
Group type: EXPERIMENTAL
Intervention: Mi-Mark Helix
Number of subjects: 217
Study 1450143 — intervention group
Group type: EXPERIMENTAL
Intervention: First plastic retriever
Number of subjects: 217
Study 1450143 — intervention group
Group type: EXPERIMENTAL
Intervention: Second plastic retriever
Number of subjects: 217
Study 1450143 — intervention group
Group type: COMPARATOR
Intervention: Spencer Wells forceps
Number of subjects: 217
Study 2409990 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ethanol (10% v/v; 300 mg kg‐1 body weight for 30 min followed by 3 mg kg‐1 min‐1 for 2 hr)
Number of subjects: 6
Study 2409990 — intervention group
Group type: COMPARATOR
Intervention: Intravenous NaCl (0.15 M)
Number of subjects: 6
Study 30565779 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin initiation in women with total cholesterol > 240 mg/dL vs < 200 mg/dL during ATP-II period
Number of subjects: 34382
Study 30565779 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin initiation in women with total cholesterol > 240 mg/dL vs < 200 mg/dL during ATP-III period
Number of subjects: 34382
Study 30565779 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin initiation in women with diabetes for primary prevention
Number of subjects: 34382
Study 30565779 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin initiation in women with diabetes for secondary prevention
Number of subjects: 34382
Study 30565779 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin initiation in women with diabetes before ATP-III
Number of subjects: 34382
Study 30565779 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin initiation in women with diabetes after ATP-III
Number of subjects: 34382
Study 29124959 — intervention group
Group type: EXPERIMENTAL
Intervention: Auditory-motor integration prepractice
Number of subjects: 1